Efficacy and Safety of First-Line Immunotherapy in Combination with Chemotherapy for Patients with Extensive-Stage Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis

Figure 4

Risk ratios for the pairwise comparisons of the network meta-analysis. Direct and indirect comparisons should be read from left to right. For overall survival, progression-free survival, and adverse events, a risk ratio of less than 1 favors the left treatment. For the objective response rate and disease control rate, a risk ratio of less than 1 favors the right treatment. ATE indicates atezolizumab; DUR indicates durvalumab; IPI indicates ipilimumab; PLA indicates placebo. All these treatments were combined with chemotherapy.

(a)

(b)

(c)